Filing Flows › Puma Biotechnology (PBYI) › Q2 2026
Puma Biotechnology (PBYI) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 6, 2026
Puma Biotechnology (PBYI) reported revenue of $56.5M for the second quarter 2026 (Q2 2026), +8% from a year earlier and +26% from the quarter before. Operating margin was 13.4%, net earnings $8.2M (14.5% of revenue).
Puma Biotechnology, Q2 2026: revenue $56.5M (+8% year over year), operating margin 13.4%, net earnings $8.2M, operating cash flow $1.6M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $56.5M | +26% | +8% |
| Operating profit | $7.6M | — | +14% |
| Net earnings | $8.2M | — | +40% |
| Operating cash flow | $1.6M | -89% | -88% |
What changed
Revenue was $56.5M in Q2 2026, up 8% year over year and up 26% from the previous quarter. Product was the largest line at 95% of revenue. Product added $4.4M year over year (up 9%), 108% of the total change. Royalty declined 9%.
Operating profit was $7.6M, a 13.4% margin (up 0.8 points year over year). Of the extra revenue versus Q2 2025, 23% reached operating profit, above the 13% margin then. Total costs grew 7% against revenue growth of 8%. The fastest-growing cost line was Research & development (+22%). Net earnings were $8.2M, up 40% year over year. The effective tax rate was 0.7%.
Operating cash flow was $1.6M (down 88% year over year), 20% of net earnings. Non-cash charges added back $2.5M of depreciation and amortization and $2.0M of share-based compensation. Working capital and other items used $11.0M.
Questions
What was Puma Biotechnology's revenue in the second quarter 2026?
Puma Biotechnology (PBYI) reported revenue of $56.5M for the second quarter 2026 (Q2 2026), +8% from a year earlier and +26% from the quarter before.
Was Puma Biotechnology profitable in the second quarter 2026?
Operating profit was $7.6M (13.4% of revenue) and net earnings $8.2M.
Source: Puma Biotechnology 10-Q on SEC EDGAR.